The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.

ABSTRACT:

Background

Biological drugs are generally expensive and produce a continuously growing share of drug costs. Yet they are essential in the treatment of many chronic diseases. Biosimilars, clinically equivalent to biological originator products, are expected to restrain drug costs in the biological market.

Objective

This study aimed to examine the impact of the biosimilar market entry on the prices of the reference products in outpatient care in Finland, investigate the impact of biosimilar market entries on price competition among biological medicinal products, and examine how the prices and market shares of outpatient biosimilars have developed in Finland during 2009-2020.

Methods

This retrospective register study applied data from IQVIA covering national community ph

SUBMITTER: Luukkanen SV 

PROVIDER: S-EPMC9271098 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature